On May 14, the US Food and Drug Administration (FDA) approved belzutifan for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma.

For more information, read the FDA announcement and the Merck & Co., Inc. press release.

Posted on 5/16/2025